{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T22:34:52Z","timestamp":1791153292459,"version":"4.1.0"},"reference-count":27,"publisher":"Public Library of Science (PLoS)","issue":"3","license":[{"start":{"date-parts":[[2012,3,16]],"date-time":"2012-03-16T00:00:00Z","timestamp":1331856000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0033736","type":"journal-article","created":{"date-parts":[[2012,3,16]],"date-time":"2012-03-16T21:08:00Z","timestamp":1331932080000},"page":"e33736","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":40,"title":["Systemic and Mucosal Immune Responses to Sublingual or Intramuscular Human Papilloma Virus Antigens in Healthy Female Volunteers"],"prefix":"10.1371","volume":"7","clinical-trial-number":[{"clinical-trial-number":"nct00949572","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Zhiming","family":"Huo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara L.","family":"Bissett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raphaela","family":"Giemza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Beddows","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clarissa","family":"Oeser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J. M.","family":"Lewis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2012,3,16]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"110","DOI":"10.4161\/hv.7.1.13739","article-title":"Sublingual vaccination.","volume":"7","author":"C Czerkinsky","year":"2011","journal-title":"Hum Vaccin"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"2598","DOI":"10.1016\/j.vaccine.2010.01.013","article-title":"Enhanced humoral and cellular immune responses after sublingual immunization against human papillomavirus 16 L1 protein with adjuvants.","volume":"28","author":"HJ Cho","year":"2010","journal-title":"Vaccine"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"7851","DOI":"10.4049\/jimmunol.0803740","article-title":"Sublingual immunization with nonreplicating antigens induces antibody-forming cells and cytotoxic T cells in the female genital tract mucosa and protects against genital papillomavirus infection.","volume":"183","author":"N Cuburu","year":"2009","journal-title":"J Immunol"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"8598","DOI":"10.1016\/j.vaccine.2007.09.073","article-title":"Sublingual immunization induces broad-based systemic and mucosal immune responses in mice.","volume":"25","author":"N Cuburu","year":"2007","journal-title":"Vaccine"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"5582","DOI":"10.1016\/j.vaccine.2010.06.033","article-title":"Sublingual immunization with an HIV subunit vaccine induces antibodies and cytotoxic T cells in the mouse female genital tract.","volume":"28","author":"C Hervouet","year":"2010","journal-title":"Vaccine"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1073\/pnas.0708684105","article-title":"Sublingual vaccination with influenza virus protects mice against lethal viral infection.","volume":"105","author":"JH Song","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"e6999","DOI":"10.1371\/journal.pone.0006999","article-title":"Transient facial nerve paralysis (Bell's palsy) following intranasal delivery of a genetically detoxified mutant of Escherichia coli heat labile toxin.","volume":"4","author":"DJ Lewis","year":"2009","journal-title":"PLoS One"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.imlet.2004.11.009","article-title":"Mucosal adjuvants and anti-infection and anti-immunopathology vaccines based on cholera toxin, cholera toxin B subunit and CpG DNA.","volume":"97","author":"J Holmgren","year":"2005","journal-title":"Immunol Lett"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"35","DOI":"10.2500\/aap.2007.28.2919","article-title":"Mucosal immunization application to allergic disease: sublingual immunotherapy.","volume":"28","author":"F Frati","year":"2007","journal-title":"Allergy Asthma Proc"},{"key":"ref10","article-title":"Mucosal Delivery Routes for Optimal Immunization: Targeting Immunity to the Right Tissues.","author":"C Czerkinsky","year":"2010","journal-title":"Curr Top Microbiol Immunol"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"e25165","DOI":"10.1371\/journal.pone.0025165","article-title":"Phase I Randomised Clinical Trial of an HIV-1(CN54), Clade C, Trimeric Envelope Vaccine Candidate Delivered Vaginally.","volume":"6","author":"DJ Lewis","year":"2011","journal-title":"PLoS One"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1128\/IAI.71.2.726-732.2003","article-title":"Protective levels of diphtheria-neutralizing antibody induced in healthy volunteers by unilateral priming-boosting intranasal immunization associated with restricted ipsilateral mucosal secretory immunoglobulin a.","volume":"71","author":"KH Mills","year":"2003","journal-title":"Infect Immun"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.virol.2003.12.027","article-title":"Reactivity of human sera in a sensitive, high-throughput pseudovirus-based papillomavirus neutralization assay for HPV16 and HPV18.","volume":"321","author":"DV Pastrana","year":"2004","journal-title":"Virology"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"8585","DOI":"10.1016\/j.vaccine.2011.09.021","article-title":"Neutralization of non-vaccine human papillomavirus pseudoviruses from the A7 and A9 species groups by bivalent HPV vaccine sera.","volume":"29","author":"E Draper","year":"2011","journal-title":"Vaccine"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"6520","DOI":"10.1016\/j.vaccine.2011.07.007","article-title":"The first international standard for antibodies to HPV 16.","volume":"29","author":"M Ferguson","year":"2011","journal-title":"Vaccine"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1002\/eji.1830210917","article-title":"The early cellular and humoral immune response to primary and booster oral immunization with cholera toxin B subunit.","volume":"21","author":"DJ Lewis","year":"1991","journal-title":"Eur J Immunol"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1097\/OLQ.0b013e31820bc880","article-title":"Prevalence of human papillomavirus antibodies in males and females in England.","volume":"38","author":"S Desai","year":"2011","journal-title":"Sex Transm Dis"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1038\/sj.bjc.6603955","article-title":"Prevalence of human papillomavirus antibodies in young female subjects in England.","volume":"97","author":"M Jit","year":"2007","journal-title":"Br J Cancer"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1086\/597307","article-title":"The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16\u201326 years.","volume":"199","author":"DR Brown","year":"2009","journal-title":"J Infect Dis"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1158\/1940-6207.CAPR-09-0031","article-title":"A pooled analysis of continued prophylactic efficacy of quadrivalent human papillomavirus (Types 6\/11\/16\/18) vaccine against high-grade cervical and external genital lesions.","volume":"2","author":"SK Kjaer","year":"2009","journal-title":"Cancer Prev Res (Phila)"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/S0140-6736(09)61248-4","article-title":"Efficacy of human papillomavirus (HPV)-16\/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women.","volume":"374","author":"J Paavonen","year":"2009","journal-title":"Lancet"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1146\/annurev.micro.112408.134019","article-title":"Vaccines to prevent infections by oncoviruses.","volume":"64","author":"JT Schiller","year":"2010","journal-title":"Annu Rev Microbiol"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1016\/S1201-9712(07)60016-2","article-title":"Correlating immunity with protection for HPV infection.","volume":"11","author":"I Frazer","year":"2007","journal-title":"International Journal of Infectious Diseases"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.iac.2011.03.001","article-title":"Adjuvants and vector systems for allergy vaccines.","volume":"31","author":"P Moingeon","year":"2011","journal-title":"Immunol Allergy Clin North Am"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1365-2710.2009.01150.x","article-title":"Quadrivalent human papillomavirus (HPV) vaccine: a review of safety, efficacy, and pharmacoeconomics.","volume":"36","author":"TC Pomfret","year":"2011","journal-title":"J Clin Pharm Ther"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1093\/infdis\/154.1.175","article-title":"Effect of neutralization of gastric acid on immune responses to an oral B subunit, killed whole-cell cholera vaccine.","volume":"154","author":"JD Clemens","year":"1986","journal-title":"J Infect Dis"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1128\/IAI.21.1.158-162.1978","article-title":"Antigenicity of purified glutaraldehyde-treated cholera toxoid administered orally.","volume":"21","author":"MM Levine","year":"1978","journal-title":"Infect Immun"}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0033736","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,4]],"date-time":"2020-07-04T09:33:15Z","timestamp":1593855195000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0033736"}},"subtitle":[],"editor":[{"given":"Paulo Lee","family":"Ho","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2012,3,16]]},"references-count":27,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2012,3,16]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0033736","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,3,16]]}}}